---
title: "New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293476852.md"
description: "Artelo Biosciences announced a review in the British Journal of Clinical Pharmacology analyzing over 50 studies on non-prescription CBD. The study found that low-dose retail CBD products lack therapeutic efficacy due to insufficient bioavailability and exposure levels compared to approved medical doses. Highlighting safety concerns like drug interactions, Artelo promoted its proprietary ART12.11 composition as an optimized solution with superior pharmacokinetics to achieve clinical benefits."
datetime: "2026-07-22T12:41:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293476852.md)
  - [en](https://longbridge.com/en/news/293476852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293476852.md)
generator: "portal-rs"
---

# New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

A recent review article published in the British Journal of Clinical Pharmacology highlights that commonly available non-prescription CBD products, despite their widespread sale, have been found to be administered at doses that do not provide sufficient exposure to elicit a positive biological effect. The study indicated that the products evaluated did not meet the required levels for effectiveness, raising concerns about their potential impact. The findings underscore the importance of ensuring appropriate dosing when utilizing CBD products, as inadequate exposure levels can diminish any potential benefits. This informative research sheds light on the need for consumers to carefully consider the dosage and quality of CBD products they choose to use.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [11:00 ETSingle Ingredient Supplements: PureHealth Research Highlights a Targeted Approach to Everyday Wellness](https://longbridge.com/en/news/298113579.md)
- [19:00 ETKANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026](https://longbridge.com/en/news/297965948.md)
- [Independent Director of Atara Biotherapeutics Picks Up 272% More Stock](https://longbridge.com/en/news/298137689.md)
- [08:00 ETMinistry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio](https://longbridge.com/en/news/298210868.md)
- [RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results](https://longbridge.com/en/news/298139566.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**